MABB - Biomaterial and Bioengineering Revenue and Competitors

It consists of the development of an international and triple impact bioengineering enterprise called MABB, whose first project is the development, production and global commercialization of a new generation of metal-free dental implant systems, which in the first phase are of the passive type. and in a second phase they will be active and intelligent (to integrate into information systems), which generate not only a high economic, but also social and environmental impact. As a first innovation, MABB uses a modern ceramic nanobiomaterial called Zirconia Yttria that is characterized by being white, translucent, inert, non-corrosive, more resistant than metal, not attracting bacteria and not transmitting heat or ions to the physiological medium, unlike current metallic. It has 10 years of global casuistry and great scientific-medical acceptance. As a second innovation, MABB achieved a 100% eco-friendly production system, based on ultra high pressure injection and sintering at high temperatures that allows producing them on a high scale and at competitive costs, which activates the possibility of marketing them at prices similar to those of titanium. (Today they sell 2 to 3 times more expensive and prevents their overcrowding). Our next innovation will be to integrate our current innovations with information technologies, nanosensors, artificial intelligence and blockchain to cause a disruption in the world of general health and insurance. It should be noted that MABB is currently the only company in America with these innovations, with 12 years of experience, and that there are only 10 competing companies with such capacity versus more than 2000 that are producing traditional metal implants, which invoice as a whole more than 6,000 million dollars, with an estimated 30 million implant systems placed annually in patients.